Raloxifene concurrently stimulates osteoprotegerin and inhibits interleukin-6 production by human trabecular osteoblasts.
The DOI matches its Crossref record; 41 of the 42 references it cites were found in a registry or an index.
Abstract
Raloxifene reduces bone loss and prevents vertebral fractures in postmenopausal women. Its skeletal effects are mediated by estrogen receptors (ER) and their modulation of paracrine osteoblastic factors. Receptor activator of nuclear factor-kappa B ligand is essential for osteoclasts and enhances bone resorption, whereas osteoprotegerin (OPG) neutralizes receptor activator of nuclear factor-kappa B ligand. Here, we assessed the effects of raloxifene on OPG production in human osteoblasts (hOB). Raloxifene enhanced gene expression of ER-alpha and progesterone receptor. Moreover, raloxifene increased OPG mRNA levels and protein secretion by hOB in a dose- and time-dependent fashion by 2- to 4-fold with a maximum effect at 10(-7) M and after 72 h (P < 0.001). Treatment with the ER antagonist ICI 182,780 abrogated the effects of raloxifene on OPG production. Moreover, raloxifene enhanced osteoblastic differentiation markers, type 1 collagen secretion, and alkaline phosphatase activity by 3- and 2-fold, respectively (P < 0.001). In addition, raloxifene inhibited expression of the bone-resorbing cytokine IL-6 by 25-45% (P < 0.001). In conclusion, our data suggest that raloxifene stimulates OPG production and inhibits IL-6 production by hOB. Because OPG production increases with osteoblastic maturation, enhancement of OPG production by raloxifene could be related to its stimulatory effects on osteoblastic differentiation.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“Cell culture studies show a positive effect of estrogen (104, 378) and raloxifene (30) on OPG production by human osteoblastic cells”
From Receptor Activator of Nuclear Factor κB Ligand and Osteoprotegerin Regulation of Bone Remodeling in Health and Disease (2008) · cites this paper as [30]
Citations
Cites
Writing Group for the Women's Health Initiative Investigators (2002) · JAMA: The Journal of the American Medical Association · doi:10.1001/jama.288.3.321 · Cited by 15,889
Antibodies, a laboratory manual
(1989) · Biomedicine & Pharmacotherapy · doi:10.1016/0753-3322(89)90130-3 · Cited by 12,366
Osteoprotegerin ligand is a cytokine that regulates osteoclast differentiation and activation.
Lacey, D. L., Timms, E., Tan, H.-L., Kelley, M. J., Dunstan, C. R., Burgess, T., Elliott, R., Colombero, A., Elliott, G., Scully, S., et al. (1998) · Cell · doi:10.1016/s0092-8674(00)81569-x · Cited by 5,439
Osteoprotegerin: a novel secreted protein involved in the regulation of bone density.
Simonet, W. S., Lacey, D. L., Dunstan, C. R., Kelley, M., Chang, M.-S., Lüthy, R., Nguyen, H. Q., Wooden, S., Bennett, L., Boone, T., et al. (1997) · Cell · doi:10.1016/s0092-8674(00)80209-3 · Cited by 5,130
Antibodies: A laboratory manual
J.L. (1989) · Trends in Biochemical Sciences · doi:10.1016/0968-0004(89)90307-1 · Cited by 5,089
Bone Resorption by Osteoclasts
Teitelbaum, S. L. (2000) · Science · doi:10.1126/science.289.5484.1504 · Cited by 3,962
Cummings, S. R., Eckert, S., Krueger, K. A., Grady, D., Powles, T. J., Cauley, J. A., Norton, L., Nickelsen, T., Bjarnason, N. H., Morrow, M., et al. (1999) · JAMA · doi:10.1001/jama.281.23.2189 · Cited by 1,872
Minireview: The OPG/RANKL/RANK System
Khosla, S. (2001) · Endocrinology · doi:10.1210/endo.142.12.8536 · Cited by 1,515
Li, J., Sarosi, I., Yan, X.-Q., Morony, S., Capparelli, C., Tan, H.-L., McCabe, S., Elliott, R., Scully, S., Van, G., et al. (2000) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.97.4.1566 · Cited by 1,119
Cited by
Clinical Implications of the Osteoprotegerin/RANKL/RANK System for Bone and Vascular Diseases
Hofbauer, L. C. (2004) · JAMA · doi:10.1001/jama.292.4.490 · Cited by 988
Self-citationKearns, A. E., Khosla, S., & Kostenuik, P. J. (2008) · Endocrine Reviews · doi:10.1210/er.2007-0014 · Cited by 824
Theoleyre, S., Wittrant, Y., Tat, S. K., Fortun, Y., Redini, F., & Heymann, D. (2004) · Cytokine & Growth Factor Reviews · doi:10.1016/j.cytogfr.2004.06.004 · Cited by 663
Bone Remodeling in Post-menopausal Osteoporosis
Lerner, U. H. (2006) · Journal of Dental Research · doi:10.1177/154405910608500703 · Cited by 347
The OPG/RANKL/RANK system in metabolic bone diseases.
Hofbauer, L. C., Kühne, C. A., & Viereck, V. (2004) · PubMed · Cited by 316
Self-citationSchumacher, M., Guennoun, R., Ghoumari, A., Massaad, C., Robert, F., El-Etr, M., Akwa, Y., Rajkowski, K., & Baulieu, E.-E. (2007) · Endocrine Reviews · doi:10.1210/er.2006-0050 · Cited by 164
Li, H., Xiao, H., Lin, L., Jou, D., Kumari, V., Lin, J., & Li, C. (2014) · Journal of Medicinal Chemistry · doi:10.1021/jm401144z · Cited by 161
Pathophysiological roles of osteoprotegerin (OPG)
Reid, P., & Holen, I. (2008) · European Journal of Cell Biology · doi:10.1016/j.ejcb.2008.06.004 · Cited by 144
Chang, J., Li, C.-J., Liao, H.-J., Wang, C., Wang, G., & Ho, M. (2009) · Toxicology · doi:10.1016/j.tox.2009.01.016 · Cited by 130
Delmas, P. D. (2008) · Journal of Clinical Densitometry · doi:10.1016/j.jocd.2008.02.002 · Cited by 131
Resistance Training at Eight-Repetition Maximum Reduces the Inflammatory Milieu in Elderly Women
PHILLIPS, M. D., FLYNN, M. G., MCFARLIN, B. K., STEWART, L. K., & TIMMERMAN, K. L. (2010) · Medicine & Science in Sports & Exercise · doi:10.1249/mss.0b013e3181b11ab7 · Cited by 112
Anastasilakis, A. D., Toulis, K. A., Goulis, D. G., Pοlyzos, S. A., Delaroudis, S., Giomisi, A., & Terpos, E. (2009) · Hormone and Metabolic Research · doi:10.1055/s-0029-1224109 · Cited by 109
Serum osteoprotegerin and its relationship with bone mineral density and markers of bone turnover.
Indridason, O. S., Franzson, L., & Sigurdsson, G. (2005) · Osteoporosis International · doi:10.1007/s00198-004-1699-x · Cited by 107
Yoshida, G., Kawabata, T., Takamatsu, H., Saita, S., Nakamura, S., Nishikawa, K., Fujiwara, M., Enokidani, Y., Yamamuro, T., Tabata, K., et al. (2022) · Autophagy · doi:10.1080/15548627.2021.2017587 · Cited by 99
Update on Raloxifene: Mechanism of Action, Clinical Efficacy, Adverse Effects, and Contraindications
Gizzo, S., Saccardi, C., Patrelli, T. S., Berretta, R., Capobianco, G., Gangi, S. D., Vacilotto, A., Bertocco, A. G., Noventa, M., Ancona, E., et al. (2013) · Obstetrical & Gynecological Survey · doi:10.1097/ogx.0b013e31828baef9 · Cited by 86
Atorvastatin stimulates the production of osteoprotegerin by human osteoblasts
Viereck, V., Gründker, C., Blaschke, S., Frosch, K., Schoppet, M., Emons, G., & Hofbauer, L. C. (2005) · Journal of Cellular Biochemistry · doi:10.1002/jcb.20598 · Cited by 77
Self-citationHarmankaya, N., Karlsson, J. E., Palmquist, A., Halvarsson, M., Igawa, K., Andersson, M., & Tengvall, P. (2013) · Acta Biomaterialia · doi:10.1016/j.actbio.2013.02.040 · Cited by 79
Role of full-length osteoprotegerin in tumor cell biology
Zauli, G., Melloni, E., Capitani, S., & Secchiero, P. (2008) · Cellular and Molecular Life Sciences · doi:10.1007/s00018-008-8536-x · Cited by 80
Yoshida, G., & ヨシダ, ゴ. (n.d.) · OUKA (Osaka University Knowledge Archive) (Osaka University) · Cited by 76
Chitosan-based biomaterials for the treatment of bone disorders
Rahimi, M., Mir, S. M., Baghban, R., Charmi, G., Plummer, C. M., Shafiei‐Irannejad, V., Soleymani, J., & Pietrasik, J. (2022) · International Journal of Biological Macromolecules · doi:10.1016/j.ijbiomac.2022.06.079 · Cited by 74
Saini, D., Fazil, M., Ali, M. M., Baboota, S., & Ali, J. (2014) · Drug Delivery · doi:10.3109/10717544.2014.900153 · Cited by 71
Pharmacological management of osteogenesis
Nardone, V., D’Asta, F., & Brandi, M. L. (2014) · Clinics · doi:10.6061/clinics/2014(06)12 · Cited by 67
Inhibition of RANKL as a treatment for osteoporosis: Preclinical and early clinical studies
McClung, M. R. (2006) · Current Osteoporosis Reports · doi:10.1007/s11914-006-0012-7 · Cited by 68
Michael, H., Härkönen, P. L., Kangas, L., Väänänen, H. K., & Hentunen, T. A. (2007) · British Journal of Pharmacology · doi:10.1038/sj.bjp.0707232 · Cited by 66
Oestrogen Receptors and Selective Oestrogen Receptor Modulators: Molecular and Cellular Pharmacology
Nilsson, S. V., & Koehler, K. F. (2005) · Basic & Clinical Pharmacology & Toxicology · doi:10.1111/j.1742-7843.2005.pto960103.x · Cited by 65
Bone Targeting Nanoparticles for the Treatment of Osteoporosis
Wen, C., Xu, X. M., Zhang, Y., Xia, J., Liang, Y., & Xu, L. (2024) · International Journal of Nanomedicine · doi:10.2147/ijn.s444347 · Cited by 63
Esposito, E., Iacono, A., Raso, G. M., Pacilio, M., Coppola, A. M., Carlo, R. D., & Meli, R. (2005) · Endocrinology · doi:10.1210/en.2005-0375 · Cited by 56
Khedgikar, V., Gautam, J., Kushwaha, P., Kumar, A., Nagar, G. K., Dixit, P., Chillara, R., Voruganti, S., Singh, S. P., Wahajuddin, M., et al. (2012) · Menopause The Journal of The North American Menopause Society · doi:10.1097/gme.0b013e318256b6ae · Cited by 54
Li, C.-J., Chang, J., Chou, C., Wang, G., & Ho, M. (2009) · Biochemical Pharmacology · doi:10.1016/j.bcp.2009.10.019 · Cited by 54
Allen, M. R., Follet, H., Khurana, M., Sato, M., & Burr, D. B. (2006) · Calcified Tissue International · doi:10.1007/s00223-006-0031-5 · Cited by 53
Rzewuska-Lech, E., Jayachandran, M., Fitzpatrick, L. A., & Miller, V. M. (2005) · American Journal of Physiology-Endocrinology and Metabolism · doi:10.1152/ajpendo.00366.2004 · Cited by 51
Ulrich‐Vinther, M. (2007) · Acta Orthopaedica · doi:10.1080/17453690610046512 · Cited by 51
Biason, T. P., Goldberg, T. B. L., Kurokawa, C. S., Moretto, M. R., Teixeira, A. S., & Nunes, H. R. D. C. (2015) · BMC Endocrine Disorders · doi:10.1186/s12902-015-0012-7 · Cited by 49
Takahata, M., Ito, M., Abe, Y., Abumi, K., & Minami, A. (2008) · Bone · doi:10.1016/j.bone.2008.08.124 · Cited by 51
Spreafico, A., Frediani, B., Capperucci, C., Leonini, A., Gambera, D., Ferrata, P., Rosini, S., Stefano, A. D., Galeazzi, M., & Marcolongo, R. (2006) · Journal of Cellular Biochemistry · doi:10.1002/jcb.20836 · Cited by 48
Isopropanolic Extract of Black Cohosh Stimulates Osteoprotegerin Production by Human Osteoblasts
Viereck, V., Gründker, C., Friess, S. C., Frosch, K., Raddatz, D., Schoppet, M., Nißlein, T., Emons, G., & Hofbauer, L. C. (2005) · Journal of Bone and Mineral Research · doi:10.1359/jbmr.050716 · Cited by 48
Self-citationTsang, S. Y., Yao, X., Essin, K., Wong, C. M., Chan, F. L., Gollasch, M., & Huang, Y. (2004) · Stroke · doi:10.1161/01.str.0000131479.08005.ca · Cited by 47
Daidzein increases OPG/RANKL ratio and suppresses IL-6 in MG-63 osteoblast cells
Sun, J., Sun, W. J., Li, Z. Y., Li, L., Wang, Y., Zhao, Y., Wang, C., Yu, L. R., Li, L. Z., & Zhang, Y. L. (2016) · International Immunopharmacology · doi:10.1016/j.intimp.2016.08.014 · Cited by 46
Messalli, E. M., & Scaffa, C. (2009) · International Journal of Women s Health · doi:10.2147/ijwh.s3894 · Cited by 44
Raloxifene therapy inhibits osteoclastogenesis during the alveolar healing process in rats
Luvizuto, E. R., Dias, S. M. D., Okamoto, T., Dornelles, R. C. M., & Okamoto, R. (2011) · Archives of Oral Biology · doi:10.1016/j.archoralbio.2011.03.015 · Cited by 47
Jochéms, C., Islander, U., Kallkopf, A., Lagerquist, M. K., Ohlsson, C., & Carlsten, H. (2007) · Arthritis & Rheumatism · doi:10.1002/art.22873 · Cited by 43
Raloxifene therapy interacts with serum osteoprotegerin in postmenopausal women
Messalli, E. M., Mainini, G., Scaffa, C., Cafiero, A. C., Salzillo, P. L., Ragucci, A., & Cobellis, L. (2006) · Maturitas · doi:10.1016/j.maturitas.2006.05.007 · Cited by 42
Rachner, T. D., Benad, P., Rauner, M., Goettsch, C., Singh, S. K., Schoppet, M., & Hofbauer, L. C. (2009) · Journal of Cellular Biochemistry · doi:10.1002/jcb.22232 · Cited by 41
Self-citationKallio, A., Guo, T., Lamminen, E., Seppänen, J., Kangas, L., Väänänen, H. K., & Härkönen, P. L. (2008) · Molecular and Cellular Endocrinology · doi:10.1016/j.mce.2008.03.005 · Cited by 40
Olivier, S., Fillet, M., Malaise, M., Piette, J. G., Bours, V., Merville, M., & Franchimont, N. (2005) · Biochemical Pharmacology · doi:10.1016/j.bcp.2004.11.030 · Cited by 40
RANKL inhibition for the management of patients with benign metabolic bone disorders
Anastasilakis, A. D., Toulis, K. A., Pοlyzos, S. A., & Terpos, E. (2009) · Expert Opinion on Investigational Drugs · doi:10.1517/13543780903048929 · Cited by 39
Chung, M., Cheng, P., Lam, K., Chen, S., Ting, Y.-F., Yen, M., & Lee, Y. (2010) · Menopause The Journal of The North American Menopause Society · doi:10.1097/gme.0b013e3181b4c4ac · Cited by 33
Effect of Cold Atmospheric Plasma (CAP) on Osteogenic Differentiation Potential of Human Osteoblasts
Eggers, B., Wagenheim, A.-M., Jung, S., Kleinheinz, J., Nokhbehsaim, M., Kramer, F., & Sielker, S. (2022) · International Journal of Molecular Sciences · doi:10.3390/ijms23052503 · Cited by 29
Raloxifene Reduces Fractures in Postmenopausal Women with Osteoporosis
Reginster, J., & Devogelaer, J. (2006) · Clinical Orthopaedics and Related Research · doi:10.1097/01.blo.0000200234.99436.24 · Cited by 29
Rachner, T. D., Schoppet, M., Niebergall, U., & Hofbauer, L. C. (2008) · Biochemical and Biophysical Research Communications · doi:10.1016/j.bbrc.2008.01.118 · Cited by 29
Self-citationRaloxifene administration enhances retention in an orthodontic relapse model
Azami, N., Chen, P., Mehta, S., Kalajzić, Ž., Dutra, E. H., Nanda, R., & Yadav, S. K. (2020) · European Journal of Orthodontics · doi:10.1093/ejo/cjaa008 · Cited by 28
Wang, Y., Yang, C., Xie, W. L., Zhao, Y. W., Li, Z. M., Sun, W. J., & Li, L. Z. (2014) · Phytomedicine · doi:10.1016/j.phymed.2014.04.012 · Cited by 28
Giner, M., Rios, M. J., Montoya, M. J., Vázquez, M. Á., Miranda, C., & Pérez‐Cano, R. (2010) · European Journal of Pharmacology · doi:10.1016/j.ejphar.2010.10.058 · Cited by 27
The use of selective estrogen receptor modulators on bone health in men
Wong, S. K., Mohamad, N.-V., Jayusman, P. A., Shuid, A. N., Ima-Nirwana, S., & Chin, K. (2018) · The Aging Male · doi:10.1080/13685538.2018.1448058 · Cited by 25
Fernández‐García, D., Muñoz‐Torres, M., Mezquita‐Raya, P., de la Higuera, M., Alonso, G., Reyes‐García, R., Ochoa, A. S., Ruiz-Requena, M. E., Luna, J. D. D., & Escobar‐Jiménez, F. (2008) · Journal of Endocrinological Investigation · doi:10.1007/bf03346385 · Cited by 26
Golden, D. A., Saria, E. A., & Hansen, M. F. (2015) · Journal of Cellular Physiology · doi:10.1002/jcp.25024 · Cited by 25
Mozzanega, B., Gizzo, S., Bernardi, D., Salmaso, L., Patrelli, T. S., Mioni, R., Finos, L., & Nardelli, G. B. (2013) · Journal of Bone and Mineral Metabolism · doi:10.1007/s00774-013-0430-4 · Cited by 24
MG63 and MC3T3-E1 Osteoblastic Cell Lines Response to Raloxifene
Muzio, L. L., Santarelli, A., Orsini, G., Memè, L., Mattioli‐Belmonte, M., Florio, I. D., Gatto, R., Gallusi, G., Nocini, P. F., Bertossi, D., et al. (2013) · European Journal of Inflammation · doi:10.1177/1721727x1301100322 · Cited by 23
Chiba, Y., Onouchi, T., Ikeda, T., Adachi, J., Tamura, Y., & Horiuchi, T. (2009) · Gerontology · doi:10.1159/000196280 · Cited by 23
Raloxifene inhibits bone loss and improves bone strength through an Opg-independent mechanism
Yan, M., Xu, Y. J., Gong, Y., Liu, J., Lu, S., Huang, L. H., Wang, Z., Zhao, Y., & Pang, X.-F. (2009) · Endocrine · doi:10.1007/s12020-009-9267-y · Cited by 23
Viereck, V., Siggelkow, H., Pannem, R., Braulke, T., Scharf, J., & Kübler, B. (2007) · Journal of Cellular Biochemistry · doi:10.1002/jcb.21274 · Cited by 22
Self-citationKarvande, A., Khedgikar, V., Kushwaha, P., Ahmad, N., Kothari, P., Verma, A., Kumar, P., Nagar, G. K., Mishra, P. R., Maurya, R., et al. (2017) · Journal of Pharmacy and Pharmacology · doi:10.1111/jphp.12764 · Cited by 19
Ahmad, N., Chillara, R., Kushwaha, P., Khedgikar, V., Karvande, A., Choudhary, D., Adhikary, S., Maurya, R., & Trivedi, R. (2017) · Biomedicine & Pharmacotherapy · doi:10.1016/j.biopha.2017.01.100 · Cited by 18
Varshosaz, J., Dayani, L., Chegini, S. P., & Minaiyan, M. (2019) · IET Nanobiotechnology · doi:10.1049/iet-nbt.2018.5252 · Cited by 17
Osteoprotegerin as a potential therapy for osteoporosis
Hamdy, N. A. T. (2006) · Current Rheumatology Reports · doi:10.1007/s11926-006-0026-2 · Cited by 17
Osteoprotegerin as a potential therapy for osteoporosis
Hamdy, N. A. T. (2005) · Current Osteoporosis Reports · doi:10.1007/s11914-996-0014-5 · Cited by 16
Ruiz-Lozano, R., Calvo‐Gallego, J. L., Pivonka, P., McDonald, M. M., & Martínez‐Reina, J. (2024) · Biomechanics and Modeling in Mechanobiology · doi:10.1007/s10237-024-01846-2 · Cited by 15
Takeda, S., Sakai, S., Shiraishi, A., Koike, N., Mihara, M., & Endo, K. (2012) · Bone · doi:10.1016/j.bone.2012.12.001 · Cited by 15
Protective effect of raloxifene on lipopolysaccharide and acid- induced acute lung injury in rats
Zhou, G., ZHANG, H., Sheng-de, Z. H. I., JIANG, G.-P., Jing, W. A. N. G., ZHANG, M., Gan, J.-X., Xu, S.-W., & Jiang, G. (2007) · Acta Pharmacologica Sinica · doi:10.1111/j.1745-7254.2007.00637.x · Cited by 14
Improving Combination Osteoporosis Therapy in a Preclinical Model of Heightened Osteoanabolism
Shao, Y., Hernandez-Buquer, S., Childress, P., Stayrook, K. R., Alvarez, M. B., Davis, H. M., Plotkin, L. I., He, Y., Condon, K. W., Burr, D. B., et al. (2017) · Endocrinology · doi:10.1210/en.2017-00355 · Cited by 13
Wang, Y., Li, L. Z., Zhang, Y. L., Zhu, Y. Q., Wu, J., & Sun, W. J. (2011) · Molecular and Cellular Endocrinology · doi:10.1016/j.mce.2011.01.018 · Cited by 13
Yue, S., Yang, Y.-L., Zhou, J.-S., Li, K.-Z., & Dou, K.-F. (2004) · World Journal of Gastroenterology · doi:10.3748/wjg.v10.i18.2750 · Cited by 11
In vivo activation of gene transcription via oestrogen response elements by a raloxifene analogue
Engdahl, C., Jochéms, C., Gustafsson, J.-Α., van der Saag, P. T., Carlsten, H., & Lagerquist, M. K. (2009) · Journal of Endocrinology · doi:10.1677/joe-09-0012 · Cited by 8
Yoh, K., Hamaya, E., Urushihara, H., Iikuni, N., Yamamoto, T., Taketsuna, M., Miyauchi, A., Sowa, H., & Tanaka, K. (2012) · Current Medical Research and Opinion · doi:10.1185/03007995.2012.736860 · Cited by 7
Chauhan, D., Dadge, S. D., Yadav, P. K., Sultana, N., Agarwal, A. K., Vishwakarma, S., Rathaur, S., Yadav, S., Chourasia, M. K., & Gayen, J. R. (2024) · Bioanalysis · doi:10.4155/bio-2023-0206 · Cited by 7
Effect of co-loaded vitamin D3 on intravenous injectable raloxifene delivery system
Chang, C., Yang, S., Young, T., & Yao, W.-C. (2024) · Colloids and Surfaces B Biointerfaces · doi:10.1016/j.colsurfb.2024.114379 · Cited by 6
Hermansen, L., Sørensen, M. M., Barckman, J., Bechtold, J. E., Søballé, K., & Baas, J. (2014) · Acta Orthopaedica · doi:10.3109/17453674.2014.958808 · Cited by 6
(2010) · Human Kinetics eBooks · doi:10.5040/9781492595700.ch-0011 · Cited by 6
Guan, G., Du, Y., Tang, W., Chen, M., Yu, W., Li, H., & Cheng, Q. (2025) · Clinical Interventions in Aging · doi:10.2147/cia.s511622 · Cited by 5
Waghmare, P. S., Kaushik, D., Öz, E., Proestos, C., Öz, F., & Kumar, M. (2025) · Inflammopharmacology · doi:10.1007/s10787-024-01633-6 · Cited by 4
Les SERMs dans le traitement de l'ostéoporose : état des lieux et perspectives
Legrand, E., Hoppé, E., Chappard, D., & Audran, M. (2006) · Gynécologie Obstétrique & Fertilité · doi:10.1016/j.gyobfe.2006.03.004 · Cited by 4
Raloxifene: A Selective Estrogen Receptor Modulator (SERM)
Dodge, J. A., & Bryant, H. U. (2012) · Wiley eBooks · doi:10.1002/9781118219683.ch15 · Cited by 4
The pharmacology of selective estrogen receptor modulators: past and present
Markovac, J., & Marcus, R. (2019) · Elsevier eBooks · doi:10.1016/b978-0-12-814841-9.00037-3 · Cited by 4
Die Rolle von RANK-Ligand und Osteoprotegerin bei Osteoporose
Hofbauer, L. C. (2004) · Journal für Kardiologie (Krause & Pachernegg GmbH) · Cited by 4
Self-citationThe Pharmacology of Selective Estrogen Receptor Modulators
Bryant, H. U. (2008) · Elsevier eBooks · doi:10.1016/b978-0-12-373884-4.00058-6 · Cited by 3
Physiological Regulation of Bone Metabolism and Estrogen Agonism
García‐Pérez, M. Á. (2006) · Springer eBooks · doi:10.1007/3-540-34742-9_7 · Cited by 3
Estrogen and raloxifene in experimental arthritis and osteoporosis
Jochéms, C. (2008) · Gothenburg University Publications Electronic Archive (Gothenburg University) · Cited by 3
Mirman, V. (2012) · OpenGrey (Institut de l'Information Scientifique et Technique) · Cited by 3
On the Role of Osteoprotegerin/RANK/RANKL System in the Interaction between Prostate Cancer and Bone
Penno, H. (2011) · Uppsala University Publications (Uppsala University) · Cited by 3
Park, S., Heo, H., Kim, K. W., & Pyo, S. W. (2021) · Journal of Oral Science · doi:10.2334/josnusd.21-0316 · Cited by 2
Bedeutung von RANK-Ligand und Osteoprotegerin für den Knochenstoffwechsel
Hofbauer, L. C., & Schoppet, M. (2006) · Springer eBooks · doi:10.1007/3-540-28782-5_21 · Cited by 1
Self-citationHarmankaya, N. (2014) · Gothenburg University Publications Electronic Archive (Gothenburg University) · Cited by 1
García, D. F. (2011) · Institutional Repository of the University of Granada (University of Granada) · Cited by 1
Ashley, D. T. (2010) · Dublin City University Open Access Institutional Repository (Dublin City University)
Osteoporosis and Vascular Calcification: Lesson from OPG KO Mice
Kim, N. (2005) · Journal of Korean Endocrine Society · doi:10.3803/jkes.2005.20.6.571
Viereck, V., Gründker, C., Frosch, K., Nißlein, T., Hofbauer, L. C., & Emons, G. (2006) · Journal für Kardiologie (Krause & Pachernegg GmbH)
Self-citationTitle : Novel perspectives for progesterone in HRT, with special reference to the nervous system
Schumacher, M., Guennoun, R., Ghoumari, A. M., Massaad, C., Robert, F., Akwa, Y., Rajkowski, K. M., & Baulieu, É.-É. (2007)
Estrogen receptors in health and disease
Gurjar, A. A., Khan, K., Yadav, M., Kumar, H., Chattopadhyay, N., & Sanyal, S. (2013) · Journal of Endocrinology & Reproduction · doi:10.18519/jer/2013/v17/75682
Influence of menopause on endodontic treatment
Gomes‐Filho, J. E., Martins, C., Sivieri‐Araújo, G., Santos, L., Queiroz, Í., Wayama, M. T., Yamanari, G. H., Dezan, E., & Cintra, L. T. Â. (2014) · Dental Press Endodontics · doi:10.14436/2178-3713.4.1.051-056.oar
Metadata
- Authors
- Viereck, V., Gründker, C., Blaschke, S., Niederkleine, B., Siggelkow, H., Frosch, K.-H., Raddatz, D., Emons, G., & Hofbauer, L. C.
- Affiliations
- University of Göttingen (DE)
- Philipps University of Marburg (DE)
- Corresponding author
- Viereck, Volker
- ORCID
- Venue
- The Journal of Clinical Endocrinology & Metabolism
- Publisher
- The Endocrine Society
- Published
- 2003-09
- Volume
- 88
- Issue
- 9
- Pages
- 4206-4213
- ISSN
- 0021-972X (ISSN-L)
- 1945-7197
- OpenAlex
- W1980481528
- Cited by
- 110
- References
- 42
- Citations by year
- 2026: 1 · 2025: 2 · 2024: 4 · 2022: 3 · 2021: 2 · 2020: 1 · 2019: 2 · 2018: 1 · 2017: 3 · 2016: 1 · 2015: 3 · 2014: 7 · 2013: 5 · 2012: 7
- FWCI
- 3.45
- Type
- journal article
- Language
- en
- Open access
- closed
- Locations
- The Journal of Clinical Endocrinology & Metabolism (publishedVersion)
- PubMed (publishedVersion)
- GRO (submittedVersion)
- Funders
- Eli Lilly and Company
- Deutsche Forschungsgemeinschaft (Ho 1875/2-1)
- Deutsche Krebshilfe
- Topics
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Bone Metabolism and Diseases
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Endocrinology › Estrogen and related hormone effects
- Health Sciences › Medicine › Orthopedics and Sports Medicine › Bone health and osteoporosis research
- Keywords
- raloxifene, osteoprotegerin, interleukin-6, estrogen receptor alpha, progesterone receptor, fulvestrant, osteogenic differentiation, type I collagen, alkaline phosphatase, bone resorption, RANKL, postmenopausal bone loss, selective estrogen receptor modulators
- MeSH terms
- Adult, Alkaline Phosphatase, Anti-Inflammatory Agents, Cells, Cultured, Dexamethasone, DNA, Dose-Response Relationship, Drug, Estrogen Antagonists, Female, Glycoproteins, Humans, Immunohistochemistry, Male, Osteoblasts, Procollagen, Receptors, Estrogen, Receptors, Progesterone, RNA, Messenger, Trabecular Meshwork, Protein Biosynthesis, Interleukin-6, Up-Regulation, Receptors, Tumor Necrosis Factor, Receptors, Cytoplasmic and Nuclear, Reverse Transcriptase Polymerase Chain Reaction, Selective Estrogen Receptor Modulators, Raloxifene Hydrochloride, Estrogen Receptor alpha, Estrogen Receptor beta, Osteoprotegerin
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.